• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?T细胞和自然杀伤细胞靶向治疗的评估：利妥昔单抗预防是否有作用？
Clin Cancer Res. 2009 Apr 1;15(7):2205-6. doi: 10.1158/1078-0432.CCR-08-2905. Epub 2009 Mar 17.
2
Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab.
Pediatr Transplant. 2003 Aug;7(4):277-81. doi: 10.1034/j.1399-3046.2003.00091.x.
3
Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
Transpl Int. 2003 Mar;16(3):197-201. doi: 10.1007/s00147-002-0486-x. Epub 2003 Feb 12.
4
Posttransplant lymphoproliferative disease.移植后淋巴细胞增生性疾病
Pediatr Infect Dis J. 2005 Dec;24(12):1107-8. doi: 10.1097/00006454-200512000-00017.
5
Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.儿童单倍体相合造血干细胞移植后EB病毒相关淋巴细胞增殖性疾病的抢先治疗
Am J Transplant. 2007 Jun;7(6):1648-55. doi: 10.1111/j.1600-6143.2007.01823.x.
6
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.EB病毒相关淋巴增殖性疾病使T细胞恶性肿瘤患者在接受抗CD2单克隆抗体西普利珠单抗治疗时病情复杂化。
Clin Cancer Res. 2009 Apr 1;15(7):2514-22. doi: 10.1158/1078-0432.CCR-08-1254. Epub 2009 Mar 17.
7
Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.心脏移植后用单克隆CD20抗体（利妥昔单抗）治疗移植后淋巴增殖性疾病。
J Heart Lung Transplant. 2001 Jul;20(7):770-2. doi: 10.1016/s1053-2498(00)00326-0.
8
Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.基于病毒血症和 T 细胞重建的 preemptive 利妥昔单抗：预防干细胞移植后 EBV 相关淋巴增殖性疾病的高效策略。
Br J Haematol. 2011 Nov;155(3):377-85. doi: 10.1111/j.1365-2141.2011.08855.x. Epub 2011 Sep 13.
9
Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.抗CD20单克隆抗体（利妥昔单抗）治疗小儿肝移植受者中与EB病毒相关的B细胞淋巴增殖性疾病。
J Pediatr Gastroenterol Nutr. 2002 Apr;34(4):389-93. doi: 10.1097/00005176-200204000-00014.
10
NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.当使用利妥昔单抗时，自然杀伤细胞介导的细胞溶解对于杀死爱泼斯坦-巴尔病毒转化的淋巴母细胞样B细胞至关重要。
Biomed Pharmacother. 2009 Jul;63(6):413-20. doi: 10.1016/j.biopha.2008.08.009. Epub 2008 Oct 1.

引用本文的文献

1
CD56 extranodal natural killer (NK)/T-cell lymphoma, nasal type presenting as skin ulcers in a white man.CD56 结外自然杀伤（NK）/T 细胞淋巴瘤，鼻型，表现为一名白人男性的皮肤溃疡。
JAAD Case Rep. 2016 Oct 8;2(5):390-396. doi: 10.1016/j.jdcr.2016.05.020. eCollection 2016 Sep.

本文引用的文献

1
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.EB病毒相关淋巴增殖性疾病使T细胞恶性肿瘤患者在接受抗CD2单克隆抗体西普利珠单抗治疗时病情复杂化。
Clin Cancer Res. 2009 Apr 1;15(7):2514-22. doi: 10.1158/1078-0432.CCR-08-1254. Epub 2009 Mar 17.
2
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.利妥昔单抗治疗B细胞移植后淋巴细胞增殖性疾病的疗效与安全性：一项前瞻性多中心2期研究的结果
Blood. 2006 Apr 15;107(8):3053-7. doi: 10.1182/blood-2005-01-0377. Epub 2005 Oct 27.
3
Prompt versus preemptive intervention for EBV lymphoproliferative disease.针对EBV淋巴增殖性疾病的即时干预与预防性干预
Blood. 2004 May 15;103(10):3979-81. doi: 10.1182/blood-2003-12-4287. Epub 2004 Jan 29.
4
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.异基因干细胞移植后高危患者通过分子监测和抢先使用利妥昔单抗预防爱泼斯坦-巴尔病毒淋巴增殖性疾病
Blood. 2002 Jun 15;99(12):4364-9. doi: 10.1182/blood.v99.12.4364.
5
Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique.由于T细胞去除技术的改变，来自匹配无关供者的异基因干细胞移植后EB病毒相关淋巴增殖性疾病的发病率增加。
Bone Marrow Transplant. 2002 Feb;29(4):335-9. doi: 10.1038/sj.bmt.1703362.
6
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.骨髓移植后淋巴增生性疾病的风险：一项多机构研究。
Blood. 1999 Oct 1;94(7):2208-16.
7
X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus.X连锁无丙种球蛋白血症患者不会感染爱泼斯坦-巴尔病毒：对该病毒生物学特性的启示
J Virol. 1999 Feb;73(2):1555-64. doi: 10.1128/JVI.73.2.1555-1564.1999.
8
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.
N Engl J Med. 1990 Dec 20;323(25):1723-8. doi: 10.1056/NEJM199012203232502.

T细胞和自然杀伤细胞靶向治疗的评估：利妥昔单抗预防是否有作用？

Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?

作者信息

Ambinder Richard F

机构信息

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

出版信息

Clin Cancer Res. 2009 Apr 1;15(7):2205-6. doi: 10.1158/1078-0432.CCR-08-2905. Epub 2009 Mar 17.

DOI:10.1158/1078-0432.CCR-08-2905
PMID:19293254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5792055/
Abstract

Splizimomab, an antibody that targets CD2, was studied in the treatment of T and natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.

摘要

斯普利齐单抗是一种靶向CD2的抗体，已在T细胞和自然杀伤细胞淋巴瘤治疗中进行研究，发现它与爱泼斯坦-巴尔病毒淋巴增殖性疾病有关。B细胞耗竭可能为进一步评估这种以及其他导致T细胞耗竭的有前景的抗体方法提供一个平台。